ClinicalTrials.gov is a federally mandated database with a large and growing, number of required data fields. Organizations are required to report any study being conducted under FDA auspices. One of the mandated reporting fields is the date that the FDA receives notification of a clinical trial’s initiation, with less than 3% of the studies in the database missing that information.
ClinicalTrials.gov is a federally mandated database with a large and growing, number of required data fields. Organizations are required to report any study being conducted under FDA auspices. One of the mandated reporting fields is the date that the FDA receives notification of a clinical trial’s initiation, with less than 3% of the studies in the database missing that information.
The data show an initial spike in received studies by the FDA in 2008, when organizations conducting clinical trials were first required to report a study’s initiation date. Previous to that date, the reporting had been voluntary. Since 2008 the number of pharmaceutical company sponsored studies has most certainly not grown. If anything, there has been a slight decrease in recent years as many pharmaceutical companies look for ways to target more effectively their clinical trial efforts. This is most clearly seen with Phase II studies. To be sure, drug develop is a complex and uncertain undertaking. Moreover, conducting an individual clinical trial may be becoming ever more challenging. However, there is no verifiable database that indicates that pharmaceutical industry is increasing the number of Phase II and III clinical trials it conducts.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.